Literature DB >> 20231618

Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials.

Uma N M Rao1, Sandra J Lee, Weixiu Luo, Martin C Mihm, John M Kirkwood.   

Abstract

Lymphocytic infiltration of primary cutaneous melanoma has been demonstrated to be of prognostic significance. Tumor infiltrating lymphocytes (TILs) were evaluated on histologic sections of pT4 primary cutaneous melanoma from 293 patients, accrued in protocols 1690 and 1694 of the Eastern Cooperative Oncology Group. Data for the 60-month follow-up were available. Statistical analysis of the pathologic data evaluated the correlation of regional lymph node metastasis and response to interferon therapy, overall survival, and relapse-free survival. In multivariate analysis, there was significant correlation of the presence of TILs and improved survival. The presence of TILs did not affect the survival of patients treated with interferon alfa-2b. Presence of a localized dominant tumor nodule within the primary tumor had an adverse effect on relapse-free survival (P = .044) that was also marginally present for overall survival (P = .112). The presence of TILs has prognostic but not predictive value, and the presence of a dominant nodule in the primary lesion represents a new adverse prognostic factor that should be incorporated in the evaluation of primary melanoma. This study confirmed the importance of tumor ulceration and the number of positive lymph nodes on outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20231618      PMCID: PMC3586796          DOI: 10.1309/AJCPTXMEFOVYWDA6

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  31 in total

1.  TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas.

Authors:  S Lyle; K E Salhany; D E Elder
Journal:  Mod Pathol       Date:  2000-01       Impact factor: 7.842

2.  Tumor vascularity in the prognostic assessment of primary cutaneous melanoma.

Authors:  Mohammed Kashani-Sabet; Richard W Sagebiel; Carlos M M Ferreira; Mehdi Nosrati; James R Miller
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

Review 3.  MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.

Authors:  G Zeng
Journal:  J Immunother       Date:  2001 May-Jun       Impact factor: 4.456

4.  Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement.

Authors:  K J Busam; C R Antonescu; A A Marghoob; K S Nehal; D L Sachs; J Shia; M Berwick
Journal:  Am J Clin Pathol       Date:  2001-06       Impact factor: 2.493

Review 5.  Thin melanomas.

Authors:  R King; P B Googe; M C Mihm
Journal:  Clin Lab Med       Date:  2000-12       Impact factor: 1.935

6.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

7.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

Authors:  J M Kirkwood; J G Ibrahim; V K Sondak; J Richards; L E Flaherty; M S Ernstoff; T J Smith; U Rao; M Steele; R H Blum
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

8.  Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma.

Authors:  Judit Kiss; József Tímár; Beáta Somlai; Katalin Gilde; Zsuzsanna Fejôs; István Gaudi; Andrea Ladányi
Journal:  Pathol Oncol Res       Date:  2007-03-27       Impact factor: 3.201

9.  Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690.

Authors:  U N M Rao; J Ibrahim; L E Flaherty; J Richards; J M Kirkwood
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

Review 10.  New TNM melanoma staging system: linking biology and natural history to clinical outcomes.

Authors:  Charles M Balch; Antonio C Buzaid; Seng-Jaw Soong; Michael B Atkins; Natale Cascinelli; Daniel G Coit; Irvin D Fleming; Jeffrey E Gershenwald; Alan Houghton; John M Kirkwood; Kelly M McMasters; Martin F Mihm; Donald L Morton; Douglas S Reintgen; Merrick I Ross; Arthur Sober; John A Thompson; John F Thompson
Journal:  Semin Surg Oncol       Date:  2003
View more
  22 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

Review 2.  Melanoma-associated leukoderma - immunology in black and white?

Authors:  Hadas Prag Naveh; Uma N M Rao; Lisa H Butterfield
Journal:  Pigment Cell Melanoma Res       Date:  2013-10-09       Impact factor: 4.693

3.  Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Authors:  Nancy E Thomas; Klaus J Busam; Lynn From; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Pamela A Groben; Honglin Hao; Irene Orlow; Anne S Reiner; Li Luo; Susan Paine; David W Ollila; Homer Wilcox; Colin B Begg; Marianne Berwick
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

Review 4.  Roles of the immune system in skin cancer.

Authors:  S Rangwala; K Y Tsai
Journal:  Br J Dermatol       Date:  2011-11       Impact factor: 9.302

5.  Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.

Authors:  Sarah A Weiss; Sung Won Han; Kevin Lui; Jeremy Tchack; Richard Shapiro; Russell Berman; Judy Zhong; Michelle Krogsgaard; Iman Osman; Farbod Darvishian
Journal:  Hum Pathol       Date:  2016-07-26       Impact factor: 3.466

Review 6.  The emerging role of resident memory T cells in protective immunity and inflammatory disease.

Authors:  Chang Ook Park; Thomas S Kupper
Journal:  Nat Med       Date:  2015-06-29       Impact factor: 53.440

7.  Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade.

Authors:  Chiara Secondini; Oriana Coquoz; Lorenzo Spagnuolo; Thibaud Spinetti; Sanam Peyvandi; Laura Ciarloni; Francesca Botta; Carole Bourquin; Curzio Rüegg
Journal:  Oncoimmunology       Date:  2017-04-20       Impact factor: 8.110

Review 8.  Revisiting determinants of prognosis in cutaneous melanoma.

Authors:  Sarah A Weiss; Douglas Hanniford; Eva Hernando; Iman Osman
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

9.  The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.

Authors:  Anton Uryvaev; Maria Passhak; Dov Hershkovits; Edmond Sabo; Gil Bar-Sela
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

Review 10.  Immunotherapy of cancer in 2012.

Authors:  John M Kirkwood; Lisa H Butterfield; Ahmad A Tarhini; Hassane Zarour; Pawel Kalinski; Soldano Ferrone
Journal:  CA Cancer J Clin       Date:  2012-05-10       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.